DDX17 Antibody (C-9): sc-271112
- DDX17 Antibody (C-9) is a mouse monoclonal IgG1 κ, cited in 7 publications, provided at 200 µg/ml
- raised against amino acids 485-641 mapping near the C-terminus of DDX17 of human origin
- recommended for detection of DDX17 of mouse, rat and human origin by WB, IP, IF, IHC(P) and ELISA
- m-IgG Fc BP-HRP and m-IgG1 BP-HRP are the preferred secondary detection reagents for DDX17 Antibody (C-9) for WB and IHC(P) applications. These reagents are now offered in bundles with DDX17 Antibody (C-9) (see ordering information below).
DDX17 Antibody (C-9) is a mouse monoclonal IgG1 antibody that detects DDX17 in mouse, rat, and human samples through various applications including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry, and enzyme-linked immunosorbent assay (ELISA). DDX17, also known as p72, is a member of the DEAD box protein family characterized by the conserved motif Asp-Glu-Ala-Asp, which plays a crucial role as a putative RNA helicase involved in essential cellular processes such as translation initiation, nuclear and mitochondrial splicing, and the assembly of ribosomes and spliceosomes. DDX17 influences gene expression and cellular growth, with implications in developmental processes like embryogenesis and spermatogenesis. DDX17 has been shown to interact with several key transcription factors, including estrogen receptor alpha (ERα), p53, MyoD, and Runx2, acting as a transcriptional co-regulator that can modulate their activity. Dysregulation of DDX17 is associated with significant developmental disorders, such as impairments in early brain development leading to conditions like Down Syndrome, while DDX17 up-regulation has been linked to the progression of colon cancer, highlighting DDX17′s potential as a therapeutic target in cancer treatment.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
DDX17 Antibody (C-9) References:
- The role of miRNA biogenesis and DDX17 in tumorigenesis and cancer stemness. | Wu, KJ. 2020. Biomed J. 43: 107-114. PMID: 32513392
- RNA Helicase DDX17 Inhibits Hepatitis B Virus Replication by Blocking Viral Pregenomic RNA Encapsidation. | Mao, R., et al. 2021. J Virol. 95: e0044421. PMID: 34287051
- DDX17-regulated alternative splicing that produced an oncogenic isoform of PXN-AS1 to promote HCC metastasis. | Zhou, HZ., et al. 2022. Hepatology. 75: 847-865. PMID: 34626132
- DDX17 protects hepatocytes against oleic acid/palmitic acid-induced lipid accumulation. | Zhang, X., et al. 2022. Biochem Biophys Res Commun. 612: 169-175. PMID: 35533489
- DDX5 and DDX17-multifaceted proteins in the regulation of tumorigenesis and tumor progression. | Xu, K., et al. 2022. Front Oncol. 12: 943032. PMID: 35992805
- DDX17 promotes the growth and metastasis of lung adenocarcinoma. | Liu, X., et al. 2022. Cell Death Discov. 8: 425. PMID: 36273228
- DDX17 helicase promotes resolution of R-loop-mediated transcription-replication conflicts in human cells. | Boleslavska, B., et al. 2022. Nucleic Acids Res. 50: 12274-12290. PMID: 36453994
- DDX17 induces epithelial-mesenchymal transition and metastasis through the miR-149-3p/CYBRD1 pathway in colorectal cancer. | Zhao, G., et al. 2023. Cell Death Dis. 14: 1. PMID: 36593242
- Helicases DDX5 and DDX17 promote heterogeneity in HBV transcription termination in infected human hepatocytes. | Chapus, F., et al. 2024. J Hepatol. 81: 609-620. PMID: 38782119
- DEAD-box helicase 17 (DDX17) protects cardiac function by promoting mitochondrial homeostasis in heart failure. | Yan, M., et al. 2024. Signal Transduct Target Ther. 9: 127. PMID: 38782919
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
DDX17 Antibody (C-9) | sc-271112 | 200 µg/ml | $322.00 | |||
DDX17 Antibody (C-9): m-IgG Fc BP-HRP Bundle | sc-540206 | 200 µg Ab; 10 µg BP | $361.00 | |||
DDX17 Antibody (C-9): m-IgG1 BP-HRP Bundle | sc-541969 | 200 µg Ab; 20 µg BP | $361.00 |